Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach

Current Vascular Pharmacology

Volumn 2, Issue 3, 2004, Pages 259-270

  Yoshioka, Yasuo ^a   Tsutsumi, Yasuo ^a   Nakagawa, Shinsaku ^a   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Antibody; Immunoconjugate; Immunotoxin; Interleukin 6; PEGylation; Tumor endothelial cells; Tumor necrosis factor alpha; Tumor vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CISPLATIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOTOXIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A7; MONOCLONAL ANTIBODY B3; MONOCLONAL ANTIBODY SS1; MONOCLONAL ANTIBODY TAC; MONOCLONAL ANTIBODY TES 23; PSEUDOMONAS EXOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ZINOSTATIN;

ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; IMMUNOGENICITY; LIVER TOXICITY; NONHUMAN; PLASMA HALF LIFE; REVIEW; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR CELL; VASCULAR TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL CELLS; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; INTERLEUKIN-6; NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; ZINOSTATIN;

EID: 3042785982     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043385682     Document Type: Review

References (79)

1. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989; 339: 394-7.
2. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 1992; 89: 5867-71.
3. Mansfield E, Chiron MF, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem Soc Trans 1997; 25: 709-14.
4. Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 1991; 51: 3781-7.
5. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93: 14815-20.
6. Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988; 65: 329-35.
7. Vaickus L, Foon KA. Overview of monoclonal antibodies in the diagnosis and therapy of cancer. Cancer Invest 1991; 9: 195-209.
8. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3: 77-85.
9. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvasc Res 1991; 41: 252-72.
10. Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 1998; 16: 513-20.
11. Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, et al. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 1994; 269: 18327-31.
12. Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer 1999; 81: 148-55.
13. Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA. et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94: 3340-8.
14. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999; 5: 2311-5.
15. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
16. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
17. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
18. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 8502-7.
19. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000; 36: 675-81.
20. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997; 3: 1031-44.
21. Engert A, Martin G, Pfreundschuh M, Amlot P, Hsu SM, Diehl V, et al. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab?' fragments on solid human Hodgkin's disease tumors in mice. Cancer Res 1990; 50: 2929-35.
22. Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML. Penetration of tumor tissue by antibodies and other immunoproteins. Ann N Y Acad Sci 1991; 618: 367-82.
23. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta 1997; 1333: C1-6.
24. Kreitman RJ, Puri RK, Leland P, Lee B, Pastan I. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity. Biochemistry 1994; 33: 11637-44.
25. Brinkman A, Kortleve DJ, Schuller AG, Zwarthoff EC, Drop SL. Site-directed mutagenesis of the N-terminal region of IGF binding protein 1; analysis of IGF binding capability. FEBS Lett 1991; 291: 264-8.
26. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-36.
27. Vasmatzis G, Essand M, Brinkmann U, Lee B, Pastan I. Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis. Proc Natl Acad Sci USA 1998; 95: 300-4.
28. Chowdhury PS, Pastan I. Analysis of cloned Fvs from a phage display library indicates that DNA immunization can mimic antibody response generated by cell immunizations. J Immunol Methods 1999; 231: 83-91.
29. Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol 1999; 163: 6072-7.
30. Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ, et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 2001; 61: 5070-7.
31. Pai LH, Batra JK, FitzGerald DJ, Willingham MC, Pastan I. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Res 1992; 52: 3189-93.
32. Knusli C, Delgado C, Malik F, Domine M, Tejedor MC, Irvine AE, et al. Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br J Haematol 1992; 82: 654-63.
33. Balemans LT, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PH, Den Otter W. Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity. Cancer Immunol Immunother 1993; 37: 7-14.
34. Tsunoda S, Tsutsumi Y, Mayumi T. Molecular design of polymer-conjugated cytokines and its application for drug delivery systems. Nippon Rinsho 1998; 56: 573-8.
35. Tsunoda S, Ishikawa T, Watanabe M, Kamada H, Yamamoto Y, Tsutsumi Y, et al. Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent. Br J Haematol 2001; 112: 181-8.
36. Tsutsumi Y, Kihira T, Yamamoto S, Kubo K, Nakagawa S, Miyake M, et al. Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency. Jpn J Cancer Res 1994; 85: 9-12.
37. Tsutsumi Y, Kihira T, Tsunoda S, Kubo K, Miyake M, Kanamori T, et al. Intravenous administration of polyethylene glycol-modified tumor necrosis factor-alpha completely regressed solid tumor in Meth-A marine sarcoma model. Jpn J Cancer Res 1994; 85: 1185-8.
38. Tsutsumi Y, Kihira T, Tsunoda S, Kanamori T, Nakagawa S, Mayumi T. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer 1995; 71: 963-8.
39. Tsutsumi Y, Kihira T, Tsunoda S, Kamada H, Nakagawa S, Kaneda Y, et al. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. J Pharmacol Exp Ther 1996; 278: 1006-11.
40. Tsutsumi Y, Tsunoda S, Kamada H, Kihira T, Kaneda Y, Ohsugi Y, et al. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 1997; 77: 168-73.
41. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 1992; 89: 1643-51.
42. Pyatak PS, Abuchowski A, Davis FF. Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. Res Commun Chem Pathol Pharmacol 1980; 29: 113-27.
43. Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA 1987; 94: 1487-91.
44. Kitamura K, Takahashi T, Takashina K, Yamaguchi T, Noguchi A, Tsurumi H, et al. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun 1990; 171: 1387-94.
45. Tanaka H, Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res 1990; 50: 6615-9.
46. Furman WL, Strother D, McClain K, Bell B, Leventhal B, Pratt CB. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 2205-10.
47. Schrezenmeier H, Marsh JC, Stromeyer P, Muller H, Heimpel H, Gordon-Smith EC, et al. A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia. Br J Haematol 1995; 90: 283-92.
48. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066-76.
49. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988; 70: 177-82.
50. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74: 1241-4.
51. Navarro S, Debili N, Le Couedic JP, Klein B, Breton-Gorius J, Doly J, et al. Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. Blood 1991; 77: 461-71.
52. Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989; 143: 3949-55.
53. Wang QC, Pai LH, Debinski W, FitzGerald DJ, Pastan I. Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. Cancer Res 1993; 53: 4588-94.
54. Benhar I, Wang QC, FitzGerald D, Pastan I. Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J Biol Chem 1994; 269: 13398-404.
55. Kuan CT, Wang QC, Pastan I. Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J Biol Chem 1994; 269: 7610-6.
56. Burrows FJ, Watanabe Y, Thorpe PE. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res 1992; 52: 5954-62.
57. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
58. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
59. Utoguchi N, Mizuguchi H, Saeki K, Ikeda K, Tsutsumi Y, Nakagawa S, et al. Tumor-conditioned medium increases macromolecular permeability of endothelial cell monolayer. Cancer Lett 1995; 89: 7-14.
60. Utoguchi N, Mizuguchi H, Dantakean A, Makimoto H, Wakai Y, Tsutsumi Y, et al. Effect of tumour cell-conditioned medium on endothelial macromolecular permeability and its correlation with collagen. Br J Cancer 1996; 73: 24-8.
61. Kamada H, Tsutsumi Y, Kihira T, Tsunoda S, Yamamoto Y, Mayumi T. In vitro remodeling of tumor vascular endothelial cells using conditioned medium from various tumor cells and their sensitivity to TNF-alpha. Biochem Biophys Res Commun 2000; 268: 809-13.
62. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000; 97: 14608-13.
63. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001; 97: 652-9.
64. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-7.
65. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 93: 4167-71.
66. Motta P, Muto M, Fujita T. Three dimensional organization of mammalian adrenal cortex. A scanning electron microscopic study. Cell Tissue Res 1979; 196: 23-38.
67. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
68. Fawcett J, Harris AL, Bicknell R. Isolation and properties in culture of human adrenal capillary endothelial cells. Biochem Biophys Res Commun 1991; 174: 903-8.
69. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 1994; 16: 901-6.
70. Ghitescu LD, Crine P, Jacobson BS. Antibodies specific to the plasma membrane of rat lung microvascular endothelium. Exp Cell Res 1997; 232: 47-55.
71. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 1999; 96: 6745-50.
72. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102: 430-7.
73. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 1997; 138: 1117-24.
74. Ohizumi I, Tsunoda S, Taniguchi K, Saito H, Esaki K, Makimoto H, et al. Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats. Biochem Biophys Res Commun 1997; 236: 493-6.
75. Ohizumi I, Tsunoda S, Taniguchi K, Saito H, Esaki K, Koizumi K, et al. Identification of tumor vascular antigens by monoclonal antibodies prepared from rat-tumor-derived endothelial cells. Int J Cancer 1998; 77: 561-6.
76. Ohizumi I, Taniguchi K, Saito H, Kawata H, Tsunoda S, Makimoto H, et al. Suppression of solid tumor growth by a monoclonal antibody against tumor vasculature in rats: involvement of intravascular thrombosis and fibrinogenesis. Int J Cancer 1999; 82: 853-9.
77. Makimoto H, Koizumi K, Tsunoda S, Wakai Y, Matsui J, Tsutsumi Y, et al. Tumor vascular targeting using a tumor-tissue endothelium-specific monoclonal antibody as an effective strategy for cancer chemotherapy. Biochem Biophys Res Commun 1999; 260: 346-50.
78. Tsunoda S, Ohizumi I, Matsui J, Koizumi K, Wakai Y, Makimoto H, et al. Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy. Br J Cancer 1999; 81: 1155-61.
79. Wakai Y, Matsui J, Koizumi K, Tsunoda S, Makimoto H, Ohizumi I, et al. Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23). Jpn J Cancer Res 2000; 91: 1319-25.